AMARIN CORP PLC\UK
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
About Amarin Corp Plc\Uk
Pharmaceutical Preparations, SIC 2834
Amarin Corporation plc is a pharmaceutical enterprise focused on developing and commercializing therapeutic medicines, primarily featuring its product Vascepa (also designated as Vazkepa). The organization operates across segments that encompass product sales alongside licensing and royalty activities, distributing treatments and partnering internationally with entities such as Recordati, Biologix, Edding, CSL Seqirus, and HLS Therapeutics. Its commercial and distribution channels serve healthcare markets through out-licensing collaborations and commercial arrangements.
The enterprise maintains an international reach spanning multiple jurisdictions, including the United States, Ireland, the United Kingdom, Switzerland, and additional European and Middle Eastern territories. Amarin Corporation plc is incorporated under the laws of England and Wales, and it conducts operations with its principal executive offices established in Dublin, Ireland.
Summary of the business section of Amarin Corp Plc\Uk's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AMARIN CORP PLC\UK
- Founded
- 1993
- Headquarters
- Dublin 2, Ireland
- Address
- Spaces South Docklands, Block C, 77 Sir John Rogerson'S Quay
- Phone
- 353 1 6699 020
- Website
- amarincorp.com
- Employees
- 80, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- AMRN
- Exchange
- Nasdaq
- Shares outstanding
- 443M, Jul 24, 2026
- Public float
- $334.70M, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 1-for-20 reverse, Apr 11, 2025; 1-for-10 reverse, Jan 18, 2008; 1-for-10 reverse, Oct 19, 1998
- SEC CIK
- 897448
- CUSIP
- 023111404
- ISIN
- US0231114044
- LEI
- 5493009JFIGUFEVPK217
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Peter L. Fishman | SVP, CFO | 7,774 |
| Steven B. Ketchum | EVP, Chief Scientific Officer | 42,680 |
| David Paul Keenan | EVP, Chief Operating Officer | 13,470 |
| Jonathan Provoost | EVP, Chief Legal Officer | 5,888 |
| Aaron Berg | President and CEO | 85,648 |
| Patrice Eadon Bonfiglio | Director | 1,239 |
| Keith Horn | Director | 1,239 |
| Kostas D. Odysseas | Director | 1,239 |
| Paul Cohen | Director | 1,239 |
| Diane E. Sullivan | Director | 836 |
| Louis Sterling III | Director | 5,450 |
| Oliver O'Connor | Director | 1,239 |
| Mark DiPaolo | Director | 838 |
| Michael Torok | Director | 4,850,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Aaron Berg | $3.54M | $3.62M | $1.48M | $14 | $125 |
| FY2025 John FThero | $0 | $0 | $1.48M | $14 | $125 |
| FY2025 Karim Mikhail | $0 | $0 | $1.48M | $14 | $125 |
| FY2025 Patrick Holt | $0 | $0 | $1.48M | $14 | $125 |
| FY2024 Aaron Berg | $3.28M | $1.47M | $1.04M | $10 | $93 |
| FY2024 John FThero | $0 | $0 | $1.04M | $10 | $93 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 80 full-time employees located in six countries, of which 60% are located in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 29, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 22, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 29, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 26, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 3, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 6, 2014 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 1, 2009 | Late filing | Notification of late filing |
| Jul 13, 2000 | Name change | Name changed from AMARIN PHARMACEUTICALS PLC to AMARIN CORP PLC\UK |
| Jan 28, 1998 | Name change | Name changed from ETHICAL HOLDINGS PLC to AMARIN PHARMACEUTICALS PLC |